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Background: TN is one of the most common causes of facial pain. A higher prevalence of psychiatric co-morbidities,
especially depressive disorder, has been proven in patients with TN; however, a clear temporal-causal relationship
between TN and specific psychiatric disorders has not been well established. We performed a nationwide
population-based retrospective cohort study to explore the relationship between TN and the subsequent
development of psychiatric disorders, including schizophrenia, bipolar disorder, depressive disorder, anxiety disorder,
and sleep disorder.
Methods: We identified subjects who were newly diagnosed with TN between January 1, 2000 and December 31,
2010 in the Taiwan National Health Insurance Research Database. A comparison cohort was constructed for patients
without TN who were matched according to age and sex. All TN and control patients were observed until diagnosed
with psychiatric disorders, death, withdrawal from the National Health Institute system, or until December 31, 2010.
Results: The TN cohort consisted of 3273 patients, and the comparison cohort consisted of 13,092 matched control
patients without TN. The adjusted hazard ratio (aHR) of depressive disorder, anxiety disorder and sleep disorder in
subjects with TN was higher than that of the controls during the follow-up [aHR: 2.85 (95 % confidence interval:
2.11–3.85), aHR: 2.98 (95 % confidence interval: 2.12–4.18) and aHR: 2.17 (95 % confidence interval: 1.48–3.19),
respectively].
Conclusions: TN might increase the risk of subsequent newly diagnosed depressive disorder, anxiety disorder,
and sleep disorder, but not schizophrenia or bipolar disorder. Additional prospective studies are required to
confirm these findings.
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Trigeminal neuralgia (TN) is a common cause of
chronic orofacial pain. However, TN may also be one of
the most puzzling orofacial pain conditions and affected
patients are often difficult to treat [1, 2]. Typically, TN is
characterized by recurrent brief episodes of unilateral
electric shock-like pain, followed by asymptomatic pe-
riods without pain, in the distribution of one or more* Correspondence: wennie945@yahoo.com.tw
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provided the original work is properly crediteddivisions of the trigeminal nerve that are triggered by in-
nocuous stimuli [3]. However, in some patients a con-
stant dull background pain may persist. Therefore, based
on the clinical features, TN is categorized into typical
and atypical form, the latter characterized by a constant
background pain and, sometimes, sensory disturbances
in the affected division [1].
The annual incidence of TN is 4 to 13 per 100,000
people [4, 5]. Women are more often affected than men,
with an approximate male to female ratio of 1:1.7 [6].
This female predominance may be related to the in-
creased longevity of women compared to men. To date,
the precise mechanism for TN remains unclear. Among
a variety of causes of TN [7–9], the microvasculardistributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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and pathogenesis of TN remains controversial [2, 10].
Chronic diseases and pain, such as migraine, are fre-
quently accompanied by psychiatric abnormalities [11].
Numerous studies have tried to clarify the associations
between the migraine and psychiatric disorders in the
past decade [12–14]. However, recent years have seen
increased attention being given to the relationship be-
tween TN and psychiatric disorders such as depression,
anxiety, or sleep disturbance [15–17]. In addition, in the
past decade, there has been renewed interest in chronic
inflammation, which is also associated with the patho-
physiology of TN development [18–20]. Studies have
shown that cytokines circulating in the plasma may im-
pair the function of the blood–brain barrier (BBB) [21],
which may indicate that peripheral inflammation is asso-
ciated with the upregulation of CNS inflammation [22].
The missing link between peripheral and CNS inflam-
mation, that is, the disruption of BBB, may play a vital
role in the development of schizophrenia [23] and bipo-
lar disorder [24]. Moreover, it is crucial to remember
that chronic TN may result in psychiatric morbidities
and reduced quality of life, in addition, existence of
newly-diagnosed psychiatric disorders could be seen as
predictors of poorer treatment outcome among the pa-
tients with TN [25].
In 2014, Meskal et al. reported that patients with TN
may be at risk for cognitive impairments [26], which re-
semble those of patients with chronic pain conditions
[27–29]. However, apart from TN, other variables such
as the medicines used to treat TN (e.g., anticonvulsants),
pain-related depressive or anxiety symptoms, and the
other factors that decrease cognitive reserve such as ad-
vanced age, multiple sclerosis or other degenerative disease
of the nervous system may be alternative explanations for
cognitive deficits among patients with TN [28, 30, 31].
Nevertheless, whether TN itself is an independent risk fac-
tor for subsequent cognitive impairments or not, the cog-
nitive impairments have been shown to affect therapy
adherence, personal relationships, daily functioning, cap-
acity for work and leisure activities, and quality of life in
patients with TN [32, 33]. In 2014, He et al. demonstrated
that patients with TN exhibit increased attention toward
pain-related information and this phenomenon may be as-
sociated with the development of anxiety and depression
[34]. For sleep investigations, although many clinicians
who treat TN report that patients are rarely awakened at
night by pain attacks, Devor et al. discovered that about
60 % of the patients with TN had painful awakenings at
least occasionally and emphasized that painful awakenings
among patients with TN are in fact quite common [17].
Although the above-mentioned research has provided
insight into the association between TN and co-morbid
psychiatric disorders, most of these study results werebased on a cross-sectional study design and lacked a lon-
gitudinal perspective. Additionally, psychiatric disorders
in these studies were often evaluated using rating scales,
such as Beck Depression Inventory, Self-Rating Depres-
sion Scale, Pain Anxiety Symptoms Scale and Self-Rating
Anxiety Scale, rather than a clinical diagnosis by a
psychiatrist. Furthermore, the small sample size of these
studies provided low statistical power.
To date, national data and large-scale studies regard-
ing the association between TN and risk of subsequent
psychiatric disorders are lacking. Due to this fact and
based on the hypothesis that patients with TN may have
a higher risk of developing psychiatric disorders, espe-
cially depressive, anxiety, and sleep disorder, we designed
a nationwide population-based retrospective cohort
study to explore the possible link between these TN and
specific psychiatric disorders.Methods
Data sources
Our data set was derived from the Taiwan National
Health Insurance Research Database (NHIRD) (http://
nhird.nhri.org.tw/en/index.html). In 1995, the National
Health Insurance (NHI) program, a government-run in-
surance program with a single-payer insurance system,
was established in Taiwan. By December 2010, more
than 23 million people were enrolled nationwide, with a
coverage rate of 99.6 % [35]. This database includes the
entire patient registry and claims data from this health
insurance system, ranging from demographic data to de-
tailed orders from ambulatory and inpatient care. All
data were de-identified by encrypting the identification
codes of patients and medical facilities so that no indi-
vidual could be identified during the investigation or
processing of the database. Personal information, such
as body weight, height, laboratory findings, lifestyle, and
smoking and alcohol habits, was not available in the
NHIRD [36]. Data used to perform the analyses con-
ducted in this study were retrieved from the Longitu-
dinal Health Insurance Database 2000 (LHID 2000), a
subset of the NHIRD. LHID 2000 is a data set released
by the NHRI that contains all original claims data for 1
million randomly selected beneficiaries in the 2000
Registry of Beneficiaries.Ethics statement
The Institutional Review Board of Kaohsiung Veterans
General Hospital approved this study. Written consent
from the patients was not obtained, because the NHI
dataset consists of de-identified secondary data for re-
search purposes and the Institutional Review Board of
Kaohsiung Veterans General Hospital issued a formal
written waiver of the need for consent.
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Using data extracted from the LHID 2000, we conducted
a retrospective cohort study of patients who were newly
diagnosed with TN (ICD-9-CM code 350.1) between
January 1, 2000 and December 31, 2010. In order to en-
sure diagnostic validity and patient homogeneity, only
patients who were diagnosed with TN by a neurologist
and had at least two consensual TN diagnoses were se-
lected for the study group. The index date was defined
as the date of patients with TN who were enrolled in
our study according to the selection criteria mentioned
above. We excluded patients who were diagnosed with
TN between January 1, 1996, and December 31, 1999.
We also excluded patients who were diagnosed with psy-
chiatric disorders (A codes: A210-A219; ICD-9-CM codes:
290–319) before they were diagnosed with TN. For each
patient with TN included in the final cohort, four age- and
sex-matched comparison patients with the same index
date and without a history of psychiatric illness were ran-
domly selected from the LHID 2000. The primary clinical
outcomes assessed were schizophrenia, depressive dis-
order, bipolar disorder, anxiety disorder, and sleep dis-
order. Moreover, in order to enhance the reliability of the
diagnosis of psychiatric disorders, patients of diagnosed
psychiatric disorders based on the ICD-9-CM code in the
database were included only when the diagnostic process
or assessment was performed by a qualified psychiatrist,
which information has also been record in the same data-
base. Therefore, all TN and comparison patients were ob-
served until diagnosed with schizophrenia (ICD-9-CM
code: 295), depressive disorder (ICD-9-CM codes: 296.2,
296.3, 300.4, and 311), bipolar disorder (ICD-9-CM codes:
296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8, 296.80, and
296.89), anxiety disorder (ICD-9-CM codes: 300.0, 300.2,
300.3, 308.3, and 309.81), or sleep disorder (ICD-9-CM
codes: 780.5, 307.4 [excluding 780.51, 780.53, 780.57]) by
a psychiatrist, or until death, withdrawal from the NHI
system, or until December 31, 2010.
Statistical analysis
The incidence of newly diagnosed schizophrenia, depres-
sive disorder, bipolar disorder, anxiety disorder, or sleep
disorder in the TN and comparison patients was calcu-
lated, and independent t tests and chi-squared tests were
conducted to examine the differences in the characteris-
tics between the TN and comparison patients. A Cox
proportional-hazards regression model was constructed
to calculate the hazard ratio (HR) of schizophrenia, depres-
sive disorder, bipolar disorder, anxiety disorder, and sleep
disorder of the TN cohort and comparison cohort. In
addition, we performed a multivariate Cox proportional-
hazards regression model to adjust for possible confound-
ing variables that might have an effect on the risk of
depressive, anxiety, and sleep disorders. Control variables,such as age; sex; common co-morbidities including hyper-
tension, diabetes mellitus, dyslipidemia, coronary artery
disease, congestive heart failure, chronic pulmonary dis-
ease, and malignancy; urbanization; and monthly income
were included as covariates in the univariate model. Fac-
tors that demonstrated a moderately significant statis-
tical relationship in the univariate analysis (P < .1) were
selected in a multivariate Cox proportional-hazards re-
gression model. Subgroups were stratified according to
the duration since TN diagnosis after calculating the in-
cidence rates (per 1000 person-year) of depressive, anx-
iety, and sleep disorders, and the risk ratios in order to
investigate potential surveillance bias.
We used SAS statistical software for Windows, Version
9.3 (SAS Institute, Cary, NC, USA), for data extraction,
computation, linkage, processing, and sampling. All other
statistical analyses were performed using the SPSS statis-
tical software for Windows, Version 20 (IBM, Armonk,
NY, USA). The results of comparisons with a P value less
than .05 were considered to indicate a statistically signifi-
cant relationship.
Results
Our study sample comprised 3273 patients with TN
(61.7 % male) and 13,092 control patients without TN.
The comparisons of the demographic and clinical vari-
ables between the TN and control patients are presented
in Table 1. The median age of the patients with TN
group was 45.6 years (interquartile range, 33.9 to 54.8 y)
and the median follow-up duration was 3.08 years (inter-
quartile range, 1.92 to 3.98 y). A higher percentage of
patients with TN were observed in the group of people
aged 40–59 years.
During the follow-up period, 176 (5.4 %) patients with
TN and 267 (2.0 %) comparison patients were diagnosed
with psychiatric illnesses. The most common subsequent
psychiatric illnesses among the patients with TN were de-
pressive disorder in 73 patients (2.23 %), anxiety disorder
in 59 patients (1.80 %), and sleep disorder in 40 patients
(1.22 %). Overall, significantly higher incidences of depres-
sive disorder (P < .001), anxiety disorder (P < .001), and
sleep disorder (P < .001) were observed in the patients
with TN than in the comparison patients.
After adjusting for age, sex, co-morbidities, urbanization,
and monthly income, the results indicated that patients
with TN exhibited a markedly higher risk for subsequent
depressive disorder (adjusted hazard ratio [aHR] 2.85,
95 % confidence interval [CI] 2.11–3.85), anxiety disorder
(aHR 2.98, 95 % CI 2.12–4.18), and sleep disorder (aHR
2.17, 95 % CI 1.48–3.19) (Table 2).
A sub-analysis based on the duration of follow-up re-
vealed that the risk of newly diagnosed depressive, anx-
iety and sleep disorders were significantly elevated not
only within the first year but also more than 1 year
Table 1 Characteristics of TN and psychiatric illness and comparison subjects
TN and psychiatric illness Control cohort P values
No. 3273 13,092
Age (years)a 45.6 (33.9–54.8) 45.6 (33.9–54.8) 0.999
Distribution of age
20–39 1299 (39.7) 5196 (39.7) 0.999
40–59 1423 (43.5) 5692 (43.5) 0.999
≥60 551 (16.8) 2204 (16.8) 0.999
Sex
Female 1255 (38.3) 5020 (38.3) 0.999
Male 2018 (61.7) 8072 (61.7)
Comorbidities
Hypertension 725 (22.2) 2192 (16.7) <0.001*
Diabetes mellitus 442 (13.5) 1285 (9.8) <0.001*
Dyslipidemia 717 (21.9) 1795 (13.7) <0.001*
Coronary artery disease 25 (0.8) 91 (0.7) 0.650
Congestive heart failure 71 (2.2) 226 (1.7) 0.090
Cerebrovascular disease 134 (4.1) 421 (3.2) 0.014
Chronic pulmonary disease 591 (18.1) 1318 (10.1) <0.001*
Malignancy 48 (1.5) 213 (1.6) 0.581
Income <0.001*
Low income 1199 (36.6) 5732 (43.8)
Medium income 1315 (40.2) 4982 (38.1)
High income 759 (23.2) 2378 (18.2)
Degree of urbanization 0.072
Urban 2112 (64.5) 8172 (62.4)
Suburban 938 (28.7) 3940 (30.1)
Rural 223 (6.8) 980 (7.5)
Follow-up, yearsa 3.08 (1.92–3.98) 3.08 (1.92–3.99) 0.852
Newly diagnosed psychiatric disorders, N (%)
Schizophrenia 3 (0.09) 5 (0.04) 1.000
Bipolar disorder 1 (0.09) 6 (0.05) 0.203
Depressive disorder 73 (2.23) 103 (0.79) <0.001*
Anxiety disorder 59 (1.80) 79 (0.60) <0.001*
Sleep disorder 40 (1.22) 74 (0.57) <0.001*
aMedian (interquartile range)
*Statistical significance
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are summarized in Table 3.
Discussion
In our study, a nationwide retrospective cohort study
was performed to investigate the hazard ratio of newly
diagnosed psychiatric disorders following a diagnosis of
TN between the patients with TN and the comparison
cohort without TN. The main finding of our study
yielded an aHR of depressive disorder that was 2.85 times
greater for patients with TN than for the comparisoncohort (Table 2). We also found that subjects with TN
were more likely to develop anxiety and sleep disorders
than the controls during the follow-up period. Further-
more, our analysis showed that hypertension, diabetes
mellitus, dyslipidemia and chronic pulmonary disease
were more prevalent in patients with TN than in patients
without TN (Table 1), which is consistent with the results
of previous studies, with the exception of chronic pulmon-
ary disease [37, 6, 38–41].
Based on our results, the patients with TN exhibited
no higher risk for subsequent schizophrenia and bipolar
Table 2 Hazard ratios of time until psychiatric illness between
TN and comparison subjects during a 10-year follow-up period
Crude HR (95 % CI) Adjusted HR (95 % CI)b
Schizophrenia 2.40 (0.35–10.03) 2.40 (0.35–10.03)
Bipolar disorder 0.67 (0.08–5.55) 0.69 (0.08–5.76)
Depressive disorder 2.87 (2.13–3.87)a 2.85 (2.11–3.85)a
Anxiety disorder 3.02 (2.15–4.23)a 2.98 (2.12–4.18)a
Sleep disorder 2.18 (1.48–3.20)a 2.17 (1.48–3.19)a
HR hazard ratio; CI confidence interval
aStatistical significance
bAdjusted for age, sex, hypertension, diabetes mellitus, dyslipidemia, coronary
artery disease, congestive heart failure, cerebrovascular disease, chronic
pulmonary disease, malignancy, income and urbanization
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mazepine (CBZ) is the first-line medical treatments for
pain control in patients with TN [42]. The initial number
of responders was 98 % with CBZ at a median dosage of
600 mg (range 200–1200 mg) [43]. However, based on
the perspective of psychiatry, since the early 1970s, CBZ
has also been used in the treatment of bipolar disorder,
both in acute mania and maintenance therapy. In
addition, CBZ was found to have strong preclinical data
for the treatment of co-morbid bipolar disorder and
chronic pain [44]. Therefore, the association between
TN and bipolar disorder may be underestimated under
the CBZ use.
Several studies have confirmed that depression and
anxiety are the most common co-morbidities in patients
with TN [45, 34, 46]. Our results indicate that TN might
be a risk factor for subsequent depressive and anxiety
disorders. There are several possible explanations for
these results regarding increased risk of new-onsetTable 3 Number of newly diagnosed depressive, anxiety and sleep
stratified by follow-up duration
Follow-up duration (year) TN and psychiatric illness




Follow-up duration (year) TN and psychiatric illness




Follow-up duration (year) TN and psychiatric illness




CI confidence interval; aStatistical significancedepressive and anxiety disorders in patients with TN.
First, TN may cause a dysregulation of central monoam-
inergic neurotransmitters, such as a decrease in sero-
tonin and norepinephrine, which is related to the
development of depressive and anxiety disorders [47,
48]. In 1997, Strittmatter et al. observed that the con-
centrations of both norepinephrine and serotonin me-
tabolites were significantly decreased in the CSF of
patients with TN. In addition, the decrease of these
monoaminergic neurotransmitters in the CSF showed a
significant negative correlation with the duration of TN
[49]. Second, a link has been demonstrated between TN
and chronic inflammation. Most of patients with TN
also suffered from chronic maxillary sinusitis, periodon-
titis, periostitis, phlegmon, and dental cysts [18], and
some studies indicate that these chronic inflammation
disorders may be a direct cause of TN development [19,
20]. Recent studies have also shown that chronic inflam-
mation plays a critical role in the pathophysiology of
schizophrenia, bipolar disorder, depressive disorder, and
anxiety disorders [50, 23, 24, 51]. Peripheral chronic in-
flammation disorders that cause TN may take longer
duration to induce similar chronic inflammation in the
central nervous system [18]. Third, Devor et al. pro-
posed the ignition hypothesis in 2002 as a possible eti-
ology of trigeminal neuralgia [52, 53]. According to this
hypothesis, TN results from specific abnormalities of
trigeminal afferent neurons in the trigeminal root or
ganglion. Injury renders axons and their somata hyper-
excitable. These hyperexcitable afferents, in turn, give
rise to pain paroxysms as a result of synchronization
after discharge activity [52]. Studies have proved that
glutamate might play an important role during thesedisorders between TN and comparison subjects which was
Control cohort Risk ratio (95 % CI)
s No. of Depressive disorder Per 1000 person-years
103 0.82 2.86 (2.09–3.90)a
24 1.84 5.36 (3.06–9.51)a
79 1.94 2.02 (1.33–3.02)a
Control cohort Risk ratio (95 % CI)
s No. of Anxiety disorder Per 1000 person-years
79 0.85 3.01 (2.11–4.27)a
20 1.53 4.01 (2.05–7.86)a
59 1.46 2.76 (1.79–4.22)a
Control cohort Risk ratio (95 % CI)
s No. of sleep disorder Per 1000 person-years
74 0.80 2.17 (1.44–3.24)a
20 1.53 2.40 (1.07–5.16)a
54 1.38 2.09 (1.27–3.35)a
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receptors [54, 55]. In addition, glutamate is a key neuro-
transmitter involved in both the peripheral and central
nervous systems. For example, glutamate produces central
sensitization of trigeminal as well as spinal cord dorsal
horn neurons [56, 57]. From the psychiatry perspective,
glutamate is the most widely used excitatory transmitter
in the central nervous system, and several studies in ani-
mals and humans have suggested that it may increase the
risk of developing depressive and anxiety disorders [58, 59,
50]. Therefore, glutamate antagonists or drugs that target
NMDA receptors may be beneficial in treating depressive
and anxiety disorders [60–62]. In short, the role of gluta-
matergic systems in the pathophysiology of TN may in-
crease the risk of subsequent depressive and anxiety
disorders.
Patients with TN often report sleep disturbances, with
awakenings caused by pain attacks. In a study of sleep
disturbance assessed by the questionnaires originated at
a conference of the Australian Trigeminal Neuralgia As-
sociation, over half of the patients with TN experienced
painful awakenings often or occasionally [17]. In our
study, patients with TN were found to have a 2.17 times
greater risk of developing a sleep disorder than the com-
parison cohort. However, only 1.22 % of patients with TN
have a sleep disorder. The wide range in the prevalence of
sleep disorders in studies of TN is likely due to the differ-
ent methods used for measuring sleep disorders.
In the present study, we conducted a subgroup ana-
lysis stratified according to the duration between the
diagnosis of TN and new-onset psychiatric illnesses
(Table 3). The results indicated that incidence of newly-
diagnosed depressive, anxiety and sleep disorders were
increased not only within the first year but also more
than 1 year after a diagnosis of TN. Patients with TN are
likely to exhibit a higher frequency of outpatient visits
than the general population, leading to an earlier diagno-
sis of psychiatric illnesses which may cause surveillance
bias. To exclude this possibility, we conducted a sub-
group analysis stratified according to the duration be-
tween the diagnosis of TN and new-onset psychiatric
disorders. The results indicated that incidence of depres-
sive, anxiety, and sleep disorders still increased after the
first year following a diagnosis of TN. Hence, concluding
that the increased risk of depressive disorder, anxiety
disorder, and sleep disorder among patients with TN in
the current study was not due to surveillance bias.
To our knowledge, this is the first large population-
based study to investigate the association between TN
and subsequent psychiatric disorders in Asian area. Large
sample size, a maximum follow-up period of 10 years, and
improving reliability of diagnosis by specialists constitute
the strengths of our study. Additionally, our study design
included an unbiased participant selection process. Inaddition, participation in the Taiwan NHI is mandatory
and all residents of Taiwan can access health care with low
copayments, therefore, referral biases are low and follow-
up compliance is high.
Certain limitations inherent to the use of health insur-
ance claims databases must be considered. First, the re-
sults of laboratory surveys and patient’s symptoms could
not be obtained from the database. Consequently, the in-
fluence of different types of TN and its severity as risk
factors for developing subsequent psychiatric disorders
could not be determined. Second, the NHIRD does not
provide detailed information on patients such as tobacco
use, alcohol consumption, body mass index, major life
events, and family history of psychiatric illnesses. These
conditions are all major risk factors for the development
of psychiatric illnesses. Therefore, we were unable to
control for these potentially confounding factors. Third,
the diagnosis of TN was identified using the ICD-9
codes from the database, and its prevalence may be
underestimated because only subjects seeking medical
evaluation can be identified; however, this would most
likely result in an underestimate of the association be-
tween TN and psychiatric illnesses. Finally, the diagnoses
in NHI claims are primarily for administrative billing,
and do not undergo verification for scientific purposes.
Therefore, validation study of NHIRD for patients with
some frequently seen diagnoses may play an essential
role on improving the quality of database study in the
future.
Conclusions
Our nationwide population-based retrospective cohort
study provides further evidence of an excessive risk of
depressive, anxiety, and sleep disorders among patients
with TN. Depressive, anxiety, and sleep disorders are
treatable psychiatric illnesses and have great impact on
the quality of life for patients with TN. Therefore, clini-
cians should be alerted to the possibility of patients with
TN developing depressive, anxiety, or sleep disorders.
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